Proposed Re-evaluation Decision PRVD2019-10, Pyriproxyfen and Its Associated End-use Products
Notice to the reader:
This consultation is now closed.
Pest Management Regulatory Agency
6 November 2019
ISSN: 1925-0967 (PDF version)
Catalogue number: H113-27/2019-10E-PDF (PDF version)
If you would like to comment, please request the full consultation document.
To obtain a full copy of Proposed Re-evaluation Decision PRVD2019-10, Pyriproxyfen and Its Associated End-use Products please contact our publications office.
Should you require further information please contact the Pest Management Information Service.
Table of Contents
- Proposed Re-evaluation Decision
- Outcome of Science Evaluation
- Proposed Regulatory Decision for Pyriproxyfen
- International Context
- Next Steps
Proposed Re-evaluation Decision
Under the authority of the Pest Control Products Act , all registered pesticides must be regularly re-evaluated by Health Canada’s Pest Management Regulatory Agency (PMRA) to ensure that they continue to meet current health and environmental standards and continue to have value. The re-evaluation considers data and information from pesticide manufacturers, published scientific reports, and other regulatory agencies. Health Canada applies internationally accepted risk assessment methods as well as current risk management approaches and policies.
Pyriproxyfen is an insect growth regulator that contributes to the management of white flies in greenhouse vegetable and ornamental production, flea control in indoor, non-food areas of structures and management of fleas on cats and dogs. Commercial products are formulated as solutions, and are applied by ground application equipment by greenhouse workers and professional applicators. Domestic-class indoor products are applied to indoor environments as a trigger pump sprayer or pressurized product. Domestic-class pet treatment products are applied to dogs as a shampoo, or to dogs and cats as a spot-on treatment. Currently registered products containing pyriproxyfen can be found in the Pesticide Label Search and in Appendix I of PRVD2019-10.
This document (Proposed Re-evaluation Decision PRVD2019-10, Pyriproxyfen and Its Associated End-use Products) presents the proposed regulatory decision for the re-evaluation of pyriproxyfen including the proposed risk mitigation measures to further protect human health and the environment, as well as the science evaluation on which the proposed decision was based. All products containing pyriproxyfen registered in Canada are subject to this proposed re-evaluation decision. PRVD2019-10 is subject to a 90-day public consultation period, during which the public including the pesticide manufacturers and stakeholders may submit written comments and additional information to the PMRA . The final re-evaluation decision will be published taking into consideration the comments and information received.
Outcome of Science Evaluation
Pyriproxyfen contributes to the management of white flies in greenhouse vegetable and ornamental production, flea control in indoor, non-food areas of structures and management of fleas on cats and dogs.
With respect to human health, dietary, residential and aggregate risks from the use of pyriproxyfen and associated end-use products have been shown to be acceptable. Occupational risks have been shown to be acceptable with label statements updated to standard baseline personal protective equipment. For indoor uses to control fleas and ticks, label amendments are proposed to standardize precautionary statements, to add best practice statements as per Regulatory Proposal PRO2018-04, Structural Pest Control Products: Label Updates and to clarify label directions to reflect actual use conditions.
When used according to the proposed label directions, potential risks to the environment from the use of pyriproxyfen and associated end-use products have been shown to be acceptable.
Proposed Regulatory Decision for Pyriproxyfen
An evaluation of available scientific information found that all uses of pyriproxyfen products meet current standards for protection of human health and the environment when used according to proposed label directions. Under the authority of the Pest Control Products Act, Health Canada is proposing that products containing pyriproxyfen are acceptable for continued registration in Canada.
Registered pesticide product labels include specific directions for use. Directions include risk mitigation measures to protect human health and the environment and must be followed by law. No products or uses are proposed for cancellation. The proposed label amendments are summarized below. Refer to Appendix VII of PRVD2019-10 for details.
- To protect mixer/loaders and applicators, updated label statements for personal protective equipment are proposed.
- Label statements are also proposed to address the following:
- Preventing recycled greenhouse water from being applied to outdoor food crops
- Prevent contamination of food and food surfaces during indoor applications
- Clarifying and/or ensuring consistency regarding use directions and precautionary statements.
- Adding best practice label statements as per PRO2018-04, Structural Pest Control Products: Label Updates
- Due to lack of data to assess occupational exposure, label statements prohibiting application using handheld mist blower or handheld fogging equipment are proposed.
- Standard label statements to inform users of the potential toxic effects of pyriproxyfen to aquatic organisms are proposed.
Pyriproxyfen is currently acceptable for use in other Organisation for Economic Co-operation and Development (OECD) member countries, including the United States, the European Union, and Australia.
As of 11 March 2019, no decision by an OECD member country to prohibit all uses of pyriproxyfen for health or environmental reasons has been identified.
The public including the registrants and stakeholders are encouraged to submit comments during the 90-day public consultation periodFootnote 1 upon publication of PRVD2019-10.
All comments received during the 90-day public consultation period will be taken into consideration in preparation of re-evaluation decision document,Footnote 2 which could result in revised risk mitigation measures. The re-evaluation decision document will include the final re‑evaluation decision, the reasons for it and a summary of comments received on the proposed re-evaluation decision with Health Canada’s responses.
Additional Scientific Information
No additional information is required at this time.
Report a problem or mistake on this page
- Date modified: